Which Tissues Retain JWH-210, RCS-4, and THC After Intravenous Dosing? An 18-Pig Study

Short answer: In a controlled pig experiment, the best specimen for detecting a cannabinoid parent compound was not necessarily the best specimen for detecting its metabolites. Six hours after separate intravenous administrations of JWH-210, RCS-4, or THC, the researchers measured different distribution patterns in lung, kidney, brain, muscle, adipose tissue, and bile. Bile was especially informative for metabolites. Vitreous humor and dura were comparatively poor choices. These findings help explain specimen selection in postmortem toxicology, but they do not convert an organ concentration into a human blood level, establish impairment, or identify a cause of death.

The primary evidence is Schaefer and colleagues’ 2017 original experiment, Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ9-Tetrahydrocannabinol After Intravenous Administration to Pigs, published in Current Neuropharmacology, DOI 10.2174/1570159X15666161111114214. The discussion below follows the study’s actual methods, original quantitative tables, and limitations rather than treating a general observation about cannabinoid lipophilicity as a case-specific conclusion.

What forensic question did this experiment answer?

When a standard blood specimen is missing or analytically uninformative, a forensic toxicologist may consider a retained organ, tissue, bile, or another available fluid. The immediate question is analytical: could a specified cannabinoid or metabolite be found in that particular material using the laboratory’s method? A separate and much harder question is whether a tissue result can establish a person’s prior blood concentration, clinical effect, or fatal mechanism. The latter conclusions do not follow merely because an assay produced a number.

This study addressed the first question experimentally. The authors administered known substances under controlled conditions and compared their six-hour tissue distributions. JWH-210 and RCS-4 were synthetic cannabinoid receptor agonists; naturally occurring delta-9-tetrahydrocannabinol served as a reference compound. Their different chemical properties made it useful to ask whether a single preferred postmortem matrix would work equally well for all three. The answer was no. Parent drugs and metabolites did not show identical patterns, and even two nearby anatomical locations could yield different concentrations.

How many animals were studied, and what exactly did they receive?

The experiment included 22 domestic pigs: six received JWH-210, six received RCS-4, six received THC, and four received a vehicle-control preparation. Thus, the three drug-treated groups comprised 18 independent animals. These are three separate treatment groups, not 18 pigs given a three-drug cocktail. The dose was 200 micrograms per kilogram of body weight for the assigned drug, administered once by the intravenous route into the jugular vein. The source reports an overall mean body weight of 44.7 ± 6.8 kg.

At 360 minutes—six hours—after administration, the animals were exsanguinated and the researchers collected cerebrum and cerebellum, right and left lungs and kidneys, liver, heart, spleen, skeletal and psoas muscle, three regions of adipose tissue, bile, dura, and vitreous humor. Samples were stored at −20°C pending analysis. Several portions and additions of analytical standards were prepared from each tissue. Those repeated portions are laboratory measurements of the same biological specimen, not additional animals. The four vehicle controls do not increase any treated group from six to ten.

This design controlled the administered agent and elapsed time; it did not represent inhaled or edible cannabis use, multiple drug exposures, repeated long-term dosing, or human deaths. It also did not collect a series of postmortem samples from the same decedent over days. That distinction matters when comparing this work to studies of postmortem redistribution or storage-temperature change.

What did the laboratory directly measure?

The physical analytical specimens were animal organs, solid tissues, bile fluid, dura, and vitreous humor. Following preparation that included enzymatic hydrolysis for many specimens and solid-phase extraction, the laboratory used liquid chromatography–tandem mass spectrometry (LC–MS/MS) to determine the parent compounds and selected hydroxylated or carboxylated metabolites. The authors employed matrix-specific standard addition: an unfortified portion and portions fortified at three known concentrations permitted an estimate of the compound already present in a specimen despite matrix-dependent response.

Original Tables 2–4 report quantitative concentrations as ng/g, including for the tabulated bile results. Those are source-reported tissue or weight-based values; they must not be silently rewritten as ng/mL of venous blood. Vitreous humor was assessed qualitatively because limited specimen volume prevented the same quantitative treatment. A low vitreous peak is therefore not an interchangeable numerical blood concentration.

The standard-addition fits in the reported quantifiable material generally had coefficients of determination between 0.96 and 0.99 for JWH-210 and THC targets and between 0.95 and 0.99 for RCS-4 targets. These coefficients describe calibrator-response relationships in the tested matrices. They are not proof of 95–99% diagnostic sensitivity, universal recovery, or accuracy in decomposed human bodies. The article does not supply, in its main tables, a single validated specimen-independent forensic reporting limit for every analyte. No such threshold should be invented.

How did parent-drug concentrations vary across organs?

The original study’s quantitative data reveal three noticeably different patterns. JWH-210 was relatively prominent in kidney tissue and had modest concentrations in lungs. RCS-4 and THC showed much higher lung concentrations. All three could be found in brain tissues six hours after their respective intravenous doses, but the brain values did not track a measured psychomotor effect or a legal intoxication threshold.

These are different animals receiving different drugs, not concentrations produced by giving the same individual all three drugs. A contrast such as 111 ng/g of RCS-4 in the right lung versus 6.9 ng/g of JWH-210 is a difference between compounds and treatment groups; it is not a controlled comparison of their pharmacological potency. The relatively large standard deviations, including 111 ± 115 ng/g in the RCS-4 lung result, caution against treating an average as an inevitable value for any particular specimen.

Why did kidneys and lungs not behave the same way?

The investigators noted that the lungs contained comparatively high RCS-4 and THC but low JWH-210, whereas the kidneys contained comparatively more JWH-210 parent compound. They discussed lipophilicity, basic chemical properties, tissue affinity, distribution, and renal handling as plausible explanations. For example, the discussion describes JWH-210 as more lipophilic than the other two compounds. These are mechanistic interpretations of observed tissue patterns—not demonstrations that one single biochemical pathway has been proven to account for the differences.

In a postmortem case, a high concentration in a lung or kidney may help decide which specimen offers an opportunity for chemical detection. It does not identify the route of intake merely from anatomical location, nor does it prove that the organ itself was injured by the drug. Intravenous administration also bypasses several processes relevant to smoking, vaping, eating, or oral-mucosal exposure. Thus the study cannot supply a universal lung-to-blood, kidney-to-blood, or tissue-to-dose conversion factor.

Why was bile particularly informative for metabolites?

Parent drugs and metabolites are separate analytical targets. Bile contained notable quantities of the hydroxylated metabolites of both synthetic cannabinoids and the hydroxylated and carboxylated metabolites of THC. The original results describe higher metabolite findings in tissues involved with metabolism or elimination, especially bile, liver, and kidneys. That is consistent with the purpose of sampling a metabolite-rich compartment rather than assuming the parent compound will remain equally visible everywhere.

The table does not imply all metabolites appeared in every organ. HO-JWH-210 was reliably identified in bile but only sporadically in several other tissues; the authors found JWH-210-COOH mainly in liver and infrequently in kidneys. RCS-4-COOH was reported in liver and kidneys and in the bile of two pigs. In the THC group, 11-HO-THC was reported in bile, and THC-COOH in bile and kidney. In other words, the absence of a selected metabolite from one compartment may be a property of the sampled matrix and timing, not proof of an absence of earlier exposure.

Could brain concentration establish psychomotor impairment?

No. The study quantified cannabinoids in dissected pig brain regions, but it did not test human visual attention, field sobriety, divided attention, reaction time, lane keeping, or crash risk. JWH-210 and THC concentrations in cerebrum were significantly lower than in cerebellum in the authors’ comparisons (p < 0.05). A difference between two brain-region chemical measurements is not a validated behavioral threshold, much less a way to calculate whether a person was fit to drive.

Even within an animal study, brain concentration at a single sampling time does not define the full time course of receptor activity or behavior. In human litigation, questions about impairment require an evidence chain involving timing, relevant performance observations, case conditions, toxicological methods, and uncertainty. The measured brain signal is evidence of distribution after a known experimental dose; it is not proof of an individual person’s mental state, judgment, or causation.

What did adipose tissue and muscle add?

All three parent compounds were observed in adipose compartments. The researchers compared dorsal, abdominal, and perirenal fat, emphasizing that anatomical subsite matters. RCS-4 concentrations in dorsal adipose tissue were significantly lower than in abdominal and perirenal fat (p < 0.05). The other parent compounds had their own descriptive distribution patterns, but the paper does not justify announcing a significant difference for every adipose comparison merely because the bars differ in its figure.

Muscle was another potential alternative specimen. For RCS-4 and THC, skeletal muscle concentrations exceeded those in psoas muscle at the study’s reported significance threshold (p < 0.05). The THC values in Table 4 were 16 ± 0.94 ng/g in skeletal muscle and 9.1 ± 3.3 ng/g in psoas. The synthetic-cannabinoid hydroxylated metabolites appeared in muscle in relatively few animals. A laboratory reporting a single unidentified “muscle” value without noting location may therefore lose important anatomical context.

Fat concentration is frequently invoked in arguments about residual drug and prior use. This experiment does support differential tissue partitioning after a known dose; it does not establish a human chronic-use schedule, a person’s precise last consumption, or a numerical estimate of released blood THC. Those would require different longitudinal and human evidence.

What did the vitreous and dura actually show?

Vitreous humor is sometimes valued in postmortem chemistry because it occupies a different anatomical environment from circulating blood. That general property does not guarantee suitability for every analyte. Here the researchers found weak qualitative peaks for JWH-210 and RCS-4 in vitreous, but no reported THC detection there. Sample volume was too low for their quantitative standard-addition analysis. No tested metabolites were detected in vitreous or dura.

Dura showed low quantifiable concentrations of JWH-210 and RCS-4 parent compounds in the tables, while THC was not found. The authors consequently viewed these relatively poorly perfused specimens as unsuitable general alternatives for this particular targeted analysis. The conclusion is not that every possible cannabinoid must be absent from every future vitreous specimen. It is that the analytical yield in this controlled experiment was limited and substance-specific. A negative vitreous or dura finding cannot automatically rebut a positive metabolite result from bile.

Can a tissue concentration be converted into a blood result?

No validated individual conversion emerges from this experiment. The paper measured selected post-dose organs and fluids at six hours. Its concentration table uses ng/g rather than a paired individual series of legal venous whole-blood cannabinoid concentrations in ng/mL. Bile, kidney, lung, brain, adipose tissue, and muscle differ in composition, perfusion, metabolism, and retention. A mathematical ratio calculated from one mean in each compartment would conceal biological variability and sampling differences, and is not a forensic back-extrapolation formula.

For an actual investigation, the specimen label, anatomical collection site, amount, handling, preservation, interval, and validated analyte panel remain critical. The broader principles of biological-matrix interpretation help keep tissue concentrations separate from venous blood results. Likewise, the requirements of specimen collection and documentation matter when deciding whether one anatomical site can fairly be compared with another.

What is the analytical significance of standard addition?

Biological tissues can suppress or enhance the ion signal during mass spectrometry. A standard curve made only in a simple solvent may respond differently from an extract of bile, fatty tissue, or decomposing organ. In standard addition, known amounts of analyte are added directly to portions of the specimen, and the native concentration is estimated from that specimen-specific response. The technique can be particularly useful when matrix effects vary strongly between specimens.

Yet standard addition is not a substitute for every validation requirement. Analysts still must establish identification criteria, carryover, internal-standard behavior, controls, blank matrix characteristics, precision, calibration, uncertainty, and applicable detection or reporting limits for the actual purpose. The authors report regression fit ranges and use stable-isotope-labeled internal standards, but the full instrumental details are in cited supplementary material. Their calibration-fit statistics cannot be converted into an unsupported claim that every tissue concentration is free of interference or exactly correct. For foundational context, see confirmatory toxicology methodology.

What findings were significant, and which limitations prevent overclaiming?

The paper reports selected inferential comparisons, rather than blanket significance for all tissue values. The cerebrum-to-cerebellum differences were significant for JWH-210 and THC; the RCS-4 dorsal-fat comparison and RCS-4/THC skeletal-versus-psoas contrasts were also reported at p < 0.05. Other numerical differences should remain descriptive unless the original paper actually reports an inferential result. In particular, a high mean plus a very high standard deviation is not an established species-wide rule.

Several limits are inseparable from the design. There were only six treated pigs per drug, and some analyte-specific table entries represent fewer quantifiable replicates. Sampling occurred at one six-hour point, so there is no tissue concentration-time curve within this experiment. The route was intravenous, not a simulation of habitual human consumption. The study did not determine person-level accuracy for forensic death classification, compare alternative collection protocols in deceased humans, or validate tissue-to-blood conversion. Animal species differences and the possibility of postmortem chemical change must be addressed separately.

How should a toxicologist use this evidence in an actual case?

Its most defensible use is to inform analyte- and specimen-specific testing strategy. If the parent drug is the target and blood is unavailable, some organ or fat specimens may have analytical value. If a metabolite is the target, bile, kidney, or liver may deserve attention. The correct choice still depends on the exact compound, validated method, postmortem condition, sampling history, and any laboratory panel that was actually run.

The report should then make a clear boundary between the confirmed chemical observation and any proposed reconstruction. A bile THC-COOH result may support a history of cannabinoid exposure in the appropriate context; it does not mean the decedent had a blood THC concentration of 383 ng/mL or was necessarily impaired at the time of an event. A positive synthetic cannabinoid signal in kidney or fat likewise identifies an analyte in a sampled compartment, not an independently established cause of death. Individual toxicological opinions require all relevant records and competing explanations, not a single extrapolation from this animal study.

Frequently asked forensic questions

1. How many drug-exposed pigs contributed to the comparisons?

Eighteen: six were dosed with JWH-210, six with RCS-4, and six with THC. There were also four vehicle-control animals, making 22 total. Multiple tissues taken from a pig and repeat standard-addition aliquots are not separate independent animals.

2. Was the same pig given JWH-210, RCS-4, and THC together?

No. Each drug-treated pig received one assigned compound intravenously. Treating the study as a combined three-drug exposure would mischaracterize its design.

3. Does a THC-COOH value in bile establish a corresponding blood THC value?

No. The 383 ± 218 ng/g figure concerns the carboxylated metabolite in pig bile, not psychoactive parent THC in human venous whole blood. There is no validated conversion here.

4. Did a negative vitreous THC result mean there was no THC exposure?

No. The THC group had documented controlled administration and parent THC in other tissues. Vitreous was a low-yield matrix in this protocol, and its analysis was qualitative owing to limited volume.

5. Can the pig tissue findings establish how long a human used a synthetic cannabinoid?

No. The experiment used one intravenous dose and a single six-hour collection time. Human route, repeated use, metabolism, specimen changes, and time since exposure require different evidence.

6. Did the study identify a safe or unsafe brain concentration?

No. Brain chemical concentrations were measured, but no individual cognitive-impairment threshold, driving task, or fatality criterion was validated.

7. Why might a confirmatory laboratory test bile as well as an organ?

The study found relatively abundant selected metabolites in bile even where they were sparse in other tissues. A combined, validated specimen strategy can improve opportunities for identifying an exposure, although positive identification still cannot alone establish individual impairment or causation.

Bottom line: tissue selection is an identification decision, not an impairment verdict

Schaefer and colleagues demonstrated that JWH-210, RCS-4, and THC distribute differently across pig tissues after controlled single intravenous doses, and that metabolite-rich bile can add information not available from every solid organ. The evidence supports considering lung, kidney, fat, brain, muscle, and bile selectively when the intended analyte and validated analytical method justify them. It does not support treating vitreous as universally sensitive, converting ng/g of tissue to a case-specific blood concentration, inferring human consumption time, or attributing a particular injury or death to an analyte merely because it was detected.

Primary study: Schaefer N, Kettner M, Laschke MW, Schlote J, Ewald AH, Menger MD, Maurer HH, Schmidt PH. Current Neuropharmacology. 2017;15(5):713–723. doi:10.2174/1570159X15666161111114214.